Barclays sets a $13 target for SAB Biotherapeutics, implying 240% upside, as Breakthrough T1D funds SAB-142 clinical assessment.
SAB Biotherapeutics (NASDAQ:SABS) received a research grant from Breakthrough T1D to assess SAB-142 in Stage 3 type 1 diabetes patients. The study aims to evaluate the therapy’s ability to preserve C-peptide and regulate immune responses in patients with residual beta cell activity.
Barclays analyst Eliana Merle initiated coverage on June 24 with an Overweight rating and a $13 price target, suggesting over 240% upside from current levels. Merle highlighted SAB-142’s potential as a disease-altering treatment, with Phase 2b data expected in the second half of 2027 as a key catalyst.
SABS focuses on developing immunotherapies for autoimmune and infectious diseases, positioning the grant and analyst upgrade as near-term drivers for the stock.